EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils

Kathleen M Buchheit iD, Dominick Shaw iD, Geoffrey Chupp iD, Lauri Lehtimaki iD, Enrico Heffler iD, Tricia Finney-Hayward iD, James Zangrilli iD, Justin Kwiatek iD, Salman Siddiqui iD, Florence Roufosse iD, Andrew Thamboo iD, Nicholas West iD und 4 weitere

Allergy · 2024-10 · 79 (10) · 2662-2679

DOI: 10.1111/all.16303 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 02.10.2024. Verfasst von Kathleen M Buchheit und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, AERD Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Interleukin-5, Eosinophils, Inflammation. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin (IL)‐5 is the key cytokine in the maturation, activation, proliferation, migration and survival of eosinophils, which are key effector cells in many upper and lower airway diseases. Through its effects on eosinophils, IL‐5 indirectly contributes to various pathophysiological processes including tissue damage, repair and remodelling. Understanding the importance of IL‐5 in eosinophil‐associated diseases led to the development of anti‐IL‐5 therapies, which provide clinical benefits across a range of conditions. However, recent evidence suggests that eosinophil‐depletion alone may not account for all of the therapeutic effects of anti‐IL‐5 therapy and that IL‐5 may also contribute to disease independently of its effects on eosinophils. Indeed, evidence from ex vivo studies and targeted therapy in vivo demonstrates that IL‐5 and its inhibition affects a much broader range of cells beyond eosinophils, including epithelial cells, plasma cells, mast cells, basophils, neutrophils, type 2 innate lymphoid cells, T regulatory cells and fibroblasts. This review will provide an update on the evidence supporting the breadth of IL‐5 biology relevant to disease pathogenesis beyond eosinophil‐associated inflammation, where there is a need for additional insight, and the clinical implications of a more central role of IL‐5 in type 2 inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-5EosinophilsInflammationHumansAnimalsCytokines

Stichwörter der Autor:innen

IL‐5airway remodellingeosinophil‐associated diseasesepitheliuminflammatory cells

Substanzen

Interleukin-5Cytokines

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, AERD Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Respiratory Medicine and Thoracic Surgery, Institute for Lung Health, Glenfield Hospital, Leicester, UK.
  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Faculty of Medicine and Health Technology, Allergy Centre, Tampere University Hospital, Tampere University, Tampere, Finland.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Personalized Medicine, Asthma and Allergy Clinic, IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Kathleen M Buchheit, Dominick Shaw, Geoffrey Chupp, Lauri Lehtimaki, Enrico Heffler, Tricia Finney-Hayward, James Zangrilli, Justin Kwiatek, Salman Siddiqui, Florence Roufosse, Andrew Thamboo, Nicholas West, Anna Vichiendilokkul, Peter W Hellings, Anju Peters, Peter H Howarth

Förderung

  • GSK
  • GlaxoSmithKline

Zitieren

APA

Buchheit, K. M., Shaw, D., Chupp, G., Lehtimaki, L., Heffler, E., Finney-Hayward, T., Zangrilli, J., Kwiatek, J., Siddiqui, S., Roufosse, F., Thamboo, A., West, N., Vichiendilokkul, A., Hellings, P. W., Peters, A., & Howarth, P. H. (2024). Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils. Allergy, 79(10), 2662-2679. https://doi.org/10.1111/all.16303

Vancouver

Buchheit KM, Shaw D, Chupp G, Lehtimaki L, Heffler E, Finney-Hayward T, et al. Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils. Allergy. 2024;79(10):2662-2679. doi:10.1111/all.16303

BibTeX
@article{Buchheit2024,
  author = {Buchheit, Kathleen M and Shaw, Dominick and Chupp, Geoffrey and Lehtimaki, Lauri and Heffler, Enrico and Finney-Hayward, Tricia and Zangrilli, James and Kwiatek, Justin and Siddiqui, Salman and Roufosse, Florence and Thamboo, Andrew and West, Nicholas and Vichiendilokkul, Anna and Hellings, Peter W and Peters, Anju and Howarth, Peter H},
  title = {Interleukin‐5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {10},
  pages = {2662--2679},
  doi = {10.1111/all.16303}
}
Kostenlos starten →